Mind Club

Data as of 11.07.2026 · Primary sources linked · NOT INVESTMENT ADVICE

Disease Pipeline Tools Obesity

Obesity

Programs, trials, and reported weight change for obesity and overweight.

Data as of 11.07.2026

All studies

Orlistat

Double-Blind, Multi-Center, Randomized Study to Assess the Efficacy and Safety of Velneperit (S-2367) and Orlistat Administered Individually or Combined With a Reduced Calorie Diet

Empros Pharma AB · Phase 2 · Completed · Enrollment 486

NCT01126970

Participants reaching a weight loss threshold

Participants reaching threshold, %

Source: Cited trial source. The denominator is the source figure, when it states one.

No selected arm reports a responder percent.

Show as table
Arm≥5%≥10%≥15%≥20%
Placebos.n/rn/rn/rn/r
Velneperit 400 mgn/rn/rn/rn/r
Orlistat 120 mgn/rn/rn/rn/r
Velneperit 400 mg + Orlistat 120 mgn/rn/rn/rn/r

Not shown

  • Placebos.: endpoint not reported
  • Velneperit 400 mg: endpoint not reported
  • Orlistat 120 mg: endpoint not reported
  • Velneperit 400 mg + Orlistat 120 mg: endpoint not reported